Premium
Treatment Options for a Patient Experiencing Pruritic Rash Associated with Transdermal Testosterone: A Review of the Literature
Author(s) -
McGriff Nayahmka J.,
Csako Gyorgy,
Kabbani Mahmoud,
Diep Long,
Chrousos George P.,
Pucino Frank
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.17.1425.34428
Subject(s) - medicine , transdermal , testosterone (patch) , rash , transdermal patch , androgen , dermatology , anesthesia , pharmacology , hormone
A 22‐year‐old man with hypogonadotropic hypogonadism was receiving monthly intramuscular injections of testosterone replacement therapy. The patient refused to self‐administer the injections because of discomfort, so the therapy was switched to testosterone patches. He experienced a pruritic, macular, erythematous rash underneath the reservoir area of two different transdermal formulations, which did not improve after pretreatment with topical corticosteroids. Eventually, he tolerated application of a testosterone gel and his serum testosterone levels returned to normal after 1 month of therapy. Commercially available and investigational testosterone products and therapeutic monitoring guidelines for androgen replacement are reviewed.